Anhui Heryi Pharmaceutical920478.BJValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 19, 2026, Anhui Heryi Pharmaceutical (920478.BJ) trades at a P/E of 164.00x, P/B of 2.34x, P/S of 7.76x, and a dividend yield of 1.00%.
Longitudinal percentile comparison: P/E sits at the 96th percentile over the trailing 10Y window (vs. 95th percentile over 3Y); P/B sits at the 55th percentile over the trailing 10Y window (vs. 49th percentile over 3Y); P/S sits at the 96th percentile over the trailing 10Y window (vs. 95th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 92nd percentile within its industry and the 88th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.00%, ranking at the 17th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 40.6 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Anhui Heryi Pharmaceutical operates in the — sector. Data refreshes weekly and is for reference only, not investment advice.
Want the full picture on whether Anhui Heryi Pharmaceutical (920478.BJ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 164.00 | ||||||
| P/B (MRQ) | 2.34 | ||||||
| P/S (TTM) | 7.76 | ||||||
| Dividend Yield | 1.00% | ||||||
| Buyback + Div Yield | 1.00% |